Trials / Completed
CompletedNCT00097045
Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C
Phase 2 Study of Omega Interferon Alone or in Combination With Ribavirin in Subjects With Hepatitis C
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (planned)
- Sponsor
- Intarcia Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to compare the safety, tolerability and antiviral effects of omega interferon administered alone to omega interferon administered with ribavirin in the treatment of subjects with chronic Hepatitis C virus (HCV) infection.
Detailed description
Omega interferon is administered subcutaneously daily for up to 48 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | omega interferon | |
| DRUG | Ribavirin |
Timeline
- Start date
- 2004-11-01
- Completion
- 2006-12-01
- First posted
- 2004-11-18
- Last updated
- 2007-08-23
Locations
3 sites across 1 country: Russia
Source: ClinicalTrials.gov record NCT00097045. Inclusion in this directory is not an endorsement.